408
Kotsaki A, Giamarellos-Bourboulis EJ. Molecular diagnosis of sepsis. Expert Opin Med Diagn.
2012;6:209–19.
Laabei M, Recker M, Rudkin JK, et al. Predicting the virulence of MRSA from its genome
sequence. Genome Res. 2014;24:839–49.
Lengauer T, Pfeifer N, Kaiser R. Personalized HIV therapy to control drug resistance. Drug Discov
Today Technol. 2014;11:57–64.
McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for
treatment of hepatitis C infection. N Engl J Med. 2009;361:580–93.
Park DJ, Lukens AK, Neafsey DE, et al. Sequence-based association and selection scans identify
drug resistance loci in the Plasmodium falciparum malaria parasite. Proc Natl Acad Sci U S A.
2012;109:13052–7.
Peretz Y, Cameron C, Sékaly RP. Dissecting the HIV-specifi c immune response: a systems biology
approach. Curr Opin HIV AIDS. 2012;7:17–23.
Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al. Peginterferon alfa-2a and ribavirin in Latino and
non-Latino whites with hepatitis C. N Engl J Med. 2009;360:257–67.
Routy JP, Boulassel MR, Yassine-Diab B, et al. Immunologic activity and safety of autologous
HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral
therapy. Clin Immunol. 2010;134:140–7.
Russo CD, Lisi L, Lofaro A, et al. Novel sensitive, specifi c and rapid pharmacogenomic test for the
prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR.
Pharmacogenomics. 2011;12:567–76.
Smith KR, Suppiah V, O’Connor K, et al. Identifi cation of improved IL28B SNPs and haplotypes
for prediction of drug response in treatment of hepatitis C using massively parallel sequencing
in a cross-sectional European cohort. Gen Med. 2011;3:57.
SPARTAC Trial Investigators. Short-course antiretroviral therapy in primary HIV infection.
N Engl J Med. 2013;368:207–17.
Toprak E, Veres A, Michel JB, et al. Evolutionary paths to antibiotic resistance under dynamically
sustained drug selection. Nat Genet. 2011;44:101–5.
Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl
J Med. 2011;365:637–46.
Watts JM, Dang KK, Gorelick RJ, et al. Architecture and secondary structure of an entire HIV-1
RNA genome. Nature. 2009;460:711–6.
Werely CJ, Donald PR, van Helden PD. NAT2 polymorphisms and their infl uence on the pharma-
cology and toxicity of isoniazid in TB patients. Pers Med. 2007;4:123–31.
Wolcott RD, Gontcharova V, Sun Y, Dowd SE. Evaluation of the bacterial diversity among and
within individual venous leg ulcers using bacterial tag-encoded FLX and titanium amplicon
pyrosequencing and metagenomic approaches. BMC Microbiol. 2009;9:226.
11 Personalized Management of Infectious Diseases